Degassing specialist Biotech Fluidics has founded Ventri Labs AB (VentriLabs).
This is a new subsidiary established to leverage the disruptive advantages of patented gravity liquid pump technology in handling sensitive media.
The use of traditional mechanical pumps is known to be detrimental to sensitive biological materials, limiting their use in bioprocessing, clinical and tissue engineering applications. This product is designed to handle sensitive media with care.
VentriLabs' gravity-based pump technology reduces the destructive mechanical and shear effects of pumping blood by up to 95% compared to commonly used peristaltic pumps, according to the company.
The technology is also more controllable, eliminating the pulsating effects inherent in peristaltic and membrane pumps. In filtration applications, this translates to increased efficiency and yields, resulting in a more cost-effective process for users.
“With multi-year funding from our parent company and a strong intellectual property portfolio, we are seeking collaboration partners and investors to accelerate our process and further develop our groundbreaking liquid pumping technology in laboratory, process and clinical applications,” said Dr. Robin Öz, CEO of VentriLabs.
